Nuclear medicines are assembled, loaded and tested at ANSTO's nuclear medicine facility before being distributed to hospitals all around Australia.
A bright future for nuclear medicine in Australia
The nuclear medicine community has welcomed the Australian Government’s decision to provide $30 million in funding to ANSTO for the design of a new nuclear medicine manufacturing facility.
Nuclear medicine products
If you’ve had a scan for heart disease or cancer, it’s likely you have benefited from the nuclear medicine manufacture and production here at ANSTO.
Tc-99m is the most important and commonly used nuclear medicine in the world today. Tc-99m is used to diagnose a variety of heart, lung, cancer and skeletal conditions.
A key role in Australia’s nuclear medicine production
Step 1 - Building 80
Step 2 - ANM Building
Step 3 - Building 23
A uranium alloy target is irradiated in the OPAL multipurpose reactor. Some of the uranium fissions into a range of isotopes, including Molybdenium-99 (Mo-99).
The manufacturing facility separates out the Mo-99. The bulk Mo-99 produced is suitable for export, but not for direct use in clinical settings.
The facility assembles, loads, tests and distributes 'finished' products including Mo-99. The Mo-99 is dispensed into an ANSTO radiopharmaceutical Gentech® Generator, where it decays to Tc-99m.